Effects of growth factors and basement membrane proteins on the phenotype of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins.
Various growth factors and basement membrane proteins have been implicated in the pathobiology of astrocytomas. The goal of this study was to determine the relative contribution of these two factors in modulating the phenotype of U-373 MG glioblastoma cells as determined by the expression of the intermediate filament proteins glial fibrillary acidic protein, vimentin, and nestin. For these determinations, cells plated in serum-free medium were treated either with growth factors binding to tyrosine kinase receptors including transforming growth factor-alpha, epidermal growth factor, platelet-derived growth factor-AA, basic fibroblast growth factor, and insulin-like growth factor-1 or with basement membrane proteins including collagen IV, laminin, and fibronectin. The changes in the expression levels of intermediate filament proteins in response to these treatments were analyzed by quantitation of immunoblots. The results demonstrate that collagen IV and growth factors binding to tyrosine kinase receptors decrease the glial fibrillary acidic protein content of U-373 MG cells. Growth factors binding to tyrosine kinase receptors also decrease the vimentin content of these cells but do not affect their nestin content. On the other hand, basement membrane proteins decrease the nestin content of U-373 MG cells but do not affect their vimentin content. The significance of these results with respect to the role played by different factors in modulating the phenotype of neoplastic astrocytes during tumor progression is discussed.
Sultana
S
S
Department of Anatomy and Cell Biology, University of Illinois at Chicago, 60612, USA.
Zhou
R
R
Sadagopan
M S
MS
Skalli
O
O
D001485:Basement Membrane / Q000737:chemistry; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D019084:Fluorescent Antibody Technique, Indirect; D005909:Glioblastoma / Q000378:metabolism* / Q000473:pathology; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D015151:Immunoblotting; D007381:Intermediate Filament Proteins / Q000378:metabolism*; D008565:Membrane Proteins / Q000494:pharmacology*; D010641:Phenotype; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D014407:Tumor Cells, Cultured
D006133:Growth Substances; D007381:Intermediate Filament Proteins; D008565:Membrane Proteins; D020794:Receptor Protein-Tyrosine Kinases